These results coupled with the low level but common amplification of the CDK6/CDK14 region of chromosome 7 observed in several human tumor types and the over-expression of CDK6 in human CRC and CRC cell lines [34], [38] suggests that therapy targeting CDK6/CDK14 activity might be beneficial at suppressing proliferation of primary and metastatic tumors. Here, CDK6 is linked to neoplasm.